An Ozempic prior authorization form is the request a prescriber sends to a patient's health plan or pharmacy benefit manager (PBM) to show that Ozempic (semaglutide) is medically necessary before the plan will pay for it. Most plans approve Ozempic for adults with type 2 diabetes, but only when the diagnosis, lab values, and treatment history are documented clearly on the form.

Below you'll find a free, payer-agnostic Ozempic PA form, direct links to the plan-specific forms for the major PBMs and government programs, the criteria reviewers actually check, and a completed example you can model your own submission on.

Free download: Get the Ozempic Prior Authorization Form (fillable PDF) here. It covers the fields major payers ask for, an attachments checklist, and a one-page reference sheet summarizing current plan criteria.

This is a general Ozempic prior authorization form that collects the information most payers ask for. Many PBMs and health plans, including Express Scripts, CVS Caremark, and OptumRx, require their own drug-specific form or an electronic PA and may not accept a general form.

What Is an Ozempic Prior Authorization Form?

An Ozempic prior authorization form is a payer-specific (or standardized) request that documents why a patient needs Ozempic and confirms they meet the plan's coverage criteria. It typically captures patient and prescriber details, the diagnosis and ICD-10 code, supporting lab values, prior diabetes therapies, and the requested dose and quantity. Depending on the plan, the same document may be called a coverage determination request, a PA request, or a prescriber criteria form.

Plans require PA for Ozempic for two reasons: cost, efficacy and safety. Ozempic is a high-cost brand GLP-1, and because semaglutide is also sold as Wegovy for weight management, payers use prior authorization to make sure Ozempic claims are for its FDA-approved uses.

Those uses have expanded. In January 2025, the FDA added an indication to reduce the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, on top of its existing glycemic control and cardiovascular risk-reduction indications.

Download the Free Ozempic Prior Authorization Form

The Develop Health Ozempic prior authorization form is a three-page PDF: a two-page request organized into ten lettered sections (A through J), plus a one-page reference sheet you read before sending. It works for initial requests, reauthorizations, appeals, and formulary or tier exceptions, with a checkbox for standard or expedited review. Fill it out once, and you'll have every answer ready, whether you submit it directly, transcribe it into an ePA portal, or attach it as supporting documentation.

Free download: Ozempic Prior Authorization Form (fillable PDF)

This is a general Ozempic prior authorization form that collects the information most payers ask for. Many PBMs and health plans, including Express Scripts, CVS Caremark, and OptumRx, require their own drug-specific form or an electronic PA and may not accept a general form.

What's Included in the Form

• A. Patient: Name, DOB, sex, member ID, group number, plan/PBM, Rx BIN, PCN, and group, plus height and weight with the date measured.
  
  

• B. Prescriber: Name, NPI, specialty, practice, office contact, phone, fax, and the dispensing pharmacy.
  
  

• C. Medication requested: Checkboxes for every Ozempic product (the 2 mg/3 mL, 4 mg/3 mL, and 8 mg/3 mL pens, single-dose syringes, and Ozempic tablets), with dose, quantity, days' supply, and refills.
  
  

• D. Diagnosis: The three labeled indications (glycemic control, MACE risk reduction with established CVD, and CKD risk reduction) with suggested ICD-10-CM codes for each.
  
  

• E. Clinical criteria: The type 2 diabetes confirmation block (A1C, fasting glucose, OGTT, or random glucose thresholds), baseline and recent A1C, metformin status, other antidiabetic classes, and CV and kidney details.
  
  

• F. Prior and current therapies: A table for each drug's dose, start and stop dates, duration, and outcome, including any prior GLP-1.
  
  

• G. Screening and labs: A1C or glucose values with dates, plus eGFR and UACR for the CKD indication.
  
  

• H. Prescriber attestations: Not for weight loss, prediabetes, or metabolic syndrome without T2D; no combination with another GLP-1 or semaglutide product; no personal or family history of medullary thyroid carcinoma or MEN 2.
  
  

• I. Reauthorization: Months on therapy, a recent A1C showing improvement or stabilization, and adherence.
  
  

• J. Attachments checklist: Dated A1C results, fill records, eGFR/UACR, recent chart notes, a copy of the pharmacy benefit card, a letter of medical necessity if the plan requires one, and the denial letter for appeals.
  
  

• Reference page: Labeled dosing and titration, example quantity limits, a snapshot of posted criteria from CVS Caremark FEP, Express Scripts/Cigna, Prime Therapeutics, an Optum Medicaid guideline, and Medicare Part D, the top denial reasons, and NovoCare manufacturer support contacts.

The reference page is dated (the current version reflects criteria posted as of September 2026). Use it as a pre-flight check, then confirm the patient's specific plan, since wording changes often.

When Payers Accept a Standardized Form

Some states require plans to accept a uniform request. California, for example, requires its licensed health care service plans to accept its uniform prescription drug prior authorization form or an equivalent ePA when they require PA.

Medicare works similarly. CMS publishes a model Request for Medicare Prescription Drug Coverage Determination that prescribers can use, and CMS guidance says written requests may be made on that model form, on a plan's own form, or on any other written document. Prescribers can likewise submit exception supporting statements in a letter, per CMS exceptions guidance.

When to Use the Payer's Own Form

For most commercial plans, the fastest route is the PBM's own form or, better yet, its electronic PA. Payer forms use branching logic that mirrors their criteria, so a mismatch between your answers and their questions can trigger a request for more information. Use our form to gather everything first, then submit through the channel your patient's plan prefers.

Check the patient's pharmacy benefit card for the BIN and PCN before you start. They tell you which PBM actually processes the claim, which is often different from the health plan name on the card.

Ozempic Prior Authorization Forms by Insurance Plan

If your patient's plan requires its own form, here's where to find it. Always confirm you have the current version, since criteria documents are updated regularly.

Commercial PBMs

All three of the largest PBMs accept electronic PA, so faxing should be the exception. Develop Health submits Ozempic PAs to Express Scripts, CVS Caremark, OptumRx, and other plans from inside your EHR, using direct PBM integrations with AI fax and phone fallback for 99%+ payer coverage. Your team reviews the auto-filled request in its existing task queue instead of logging into a separate portal for each plan.

If you’re submitting manually, each PBM lists its own channels. Express Scripts accepts ePA (through portals such as EviCore by Evernorth, CoverMyMeds, or Surescripts), verbal requests at 800-753-2851, and state-specific fax forms, per its prior authorization resources page, and its ePA questionnaire only shows the questions required for that request. OptumRx accepts ePA through several third-party portals, verbal requests at 1-800-711-4555, and fax forms, per its electronic prior authorization page. One Medicare wrinkle: when an Optum specialty or infusion pharmacy prepares a Part D PA, the prescriber has to review and submit it.

Medicare Part D and the GLP-1 Bridge

For Medicare patients with type 2 diabetes, Ozempic requests go to the patient's Part D plan. The newer Medicare GLP-1 Bridge is a separate pathway, and it's a common source of confusion. The CMS Bridge form covers Foundayo, Wegovy, and Zepbound for weight reduction only. Patients with type 2 diabetes or another Part D-eligible diagnosis must be submitted to their Part D plan instead.

In other words, the Bridge never applies to Ozempic. If you're prescribing semaglutide for weight management under the Bridge, the product is Wegovy.

TRICARE

TRICARE's Ozempic and Mounjaro form is a strict decision tree. The Martin's Point TRICARE form stops coverage immediately for weight loss without diabetes, requires metformin failure or a contraindication for most patients, and has a separate CKD pathway that asks about eGFR, ACE inhibitor or ARB use, and SGLT-2 inhibitor use. The good news: that form states approved PAs don't expire. Note that the TRICARE pharmacy program form hosted by Express Scripts is an older version without the CKD pathway, so confirm which form applies to your patient's TRICARE plan.

Medicaid

Every state Medicaid program must cover GLP-1s for diabetes, while obesity coverage is optional. As KFF's analysis of Medicaid GLP-1 coverage explains, only 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026. Even for diabetes, PA is common. Florida Medicaid, for example, covered Ozempic for type 2 diabetes with PA as of 2025 and requires documentation that other treatments failed or can't be used.

Ozempic Prior Authorization Criteria: What Reviewers Check

Criteria differ by plan, but nearly every Ozempic PA comes down to the same five questions. If your form answers all five with documentation, you're in strong shape.

1. A Documented Type 2 Diabetes Diagnosis

This is the gatekeeper. Include the ICD-10 code (E11.x) and make sure the chart notes support it. Some plans only need the diagnosis. Cigna's employer-plan policy, as summarized by D3rx, requires documented type 2 diabetes without a metformin step or A1C threshold, and explicitly excludes weight loss without diabetes, prediabetes, and type 1 diabetes.

2. Lab Evidence That Confirms the Diagnosis

Many plans want to see the lab value behind the diagnosis. The ADA diagnostic thresholds, restated in this Wisconsin DHS reference sheet, are an A1C of 6.5% or higher, fasting plasma glucose of 126 mg/dL or higher, a 2-hour OGTT glucose of 200 mg/dL or higher, or a random glucose of 200 mg/dL or higher with classic symptoms. The current ADA Standards of Care in Diabetes 2026 remains the reference most reviewers expect.

3. Step Therapy (Usually Metformin)

This is where plans differ most. CVS Caremark's standard criteria can require at least a 90-day supply of metformin within the past 360 days with an inadequate response, unless another criterion applies. Aetna's Ozempic policy, per D3rx's summary, requires metformin failure, intolerance, or contraindication for new starts, or a need for combination therapy with an A1C of 7.5% or higher. UnitedHealthcare, by contrast, removed step therapy for GLP-1s in April 2024.

Document metformin clearly: dose, start and stop dates, and the specific reason it wasn't enough (inadequate A1C response, GI intolerance, eGFR below the threshold, and so on).

4. Cardiovascular or Kidney Indications

If your patient has type 2 diabetes plus established cardiovascular disease or chronic kidney disease, say so explicitly. Blue Cross NC's Part D criteria list separate approval paths for type 2 diabetes with established cardiovascular disease (such as prior MI, stroke, or revascularization) and for type 2 diabetes with CKD. On some plans these paths also bypass the metformin step: CVS Caremark's criteria accept documented established cardiovascular disease for Ozempic in place of a metformin trial, and the Martin's Point TRICARE form routes CKD patients around the metformin questions.

5. Quantity Limits and Safety Checks

Expect questions about dose, pens per month, and concurrent therapy. Plans such as Blue Cross NC won't approve Ozempic alongside another GLP-1 agonist or a DPP-4 inhibitor, and forms like TennCare's GLP-1 PA form ask you to confirm the patient has no personal or family history of medullary thyroid carcinoma or MEN 2, matching Ozempic's boxed warning.

If the patient is already stable on Ozempic (for example, after switching plans), request it as a continuation and document the A1C improvement since starting. Many plans, including Aetna per D3rx, apply lighter continuation criteria that skip the metformin step.

How to Fill Out the Ozempic PA Form, Step by Step

Whether you use our form or a payer's, the workflow is the same. Following it in order is the best way to avoid back-and-forth requests for more information.

Step 1: Confirm Coverage and the Right Channel

Run an eligibility and benefit check first. Confirm the PBM from the BIN/PCN, check whether Ozempic is on formulary, and find out whether the plan prefers ePA. If the plan screens claims by diagnosis code, simply adding the ICD-10 code to the prescription may clear the claim without a PA.

Step 2: Complete Patient, Insurance, and Prescriber Sections

Match the patient's name and member ID exactly as they appear on the insurance card. Include the prescriber's NPI and a secure fax number, since that's where the determination will land. Mismatched identifiers are a surprisingly common reason for administrative rejections.

Step 3: Specify the Medication Request

List the exact product, strength, dose, directions, and quantity. For a new start, include the titration plan (for example, 0.25 mg weekly for four weeks, then 0.5 mg weekly). Mark whether this is an initial request, a reauthorization, an appeal, or an exception. Ozempic now comes as both weekly pens and once-daily tablets, so name the dosage form and strength explicitly. The Develop Health form's reference page also recommends writing titration prescriptions per strength to avoid quantity-limit rejections.

Step 4: Document the Diagnosis and Clinical Evidence

Enter the ICD-10 code and the most recent A1C or glucose value with the date drawn. Add eGFR if you're using the CKD pathway, and document established cardiovascular disease with the event and date if you're using that one. Think of it like building a case file: each box on the form should point to something in the chart.

"On the prior authorization side, you should submit the diagnosis for the condition you're treating. You should delineate what you're treating." - Vinay Panchal, Head of Pharmacy Operations and PBM Relations (pharmacist, 10 years overseeing drug authorizations at Blue Shield of California).

Step 5: Record Treatment History

List every prior antidiabetic medication with dose, dates, and outcome. "Metformin – failed" is weak. "Metformin 1,000 mg BID, 03/2023–present; A1C 8.4% on 08/12/2026 despite adherence" is strong.

Step 6: Attach Documentation, Sign, and Submit

Attach dated A1C results, chart notes from the last 6 to 12 months, and fill records for each prior therapy, plus a copy of the pharmacy benefit card. Samples and manufacturer free goods usually don't count as a trial. For an appeal, include the denial letter and quote the denial reason verbatim in your response. Sign and date the attestation, then submit through the plan's preferred channel. Log the submission date and reference number so you can follow up if you haven't received a decision within the expected timeframe.

Mark a request as expedited only when a delay could seriously jeopardize the patient's health. Plans can downgrade requests that don't meet the standard, and overuse erodes credibility with reviewers.

Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound: PA Requirements Compared

Mixing up these four drugs is one of the fastest ways to get a denial. Here's how their PA pathways differ.

Coverage follows the brand's FDA indication, not the molecule. Commercial plans often route Wegovy and Zepbound through a separate weight-management policy, and KFF notes that obesity coverage at most large employers remains limited. As KFF notes, Medicaid programs must cover Wegovy for cardiovascular disease and Zepbound for sleep apnea, while obesity coverage stays optional.

If a patient without diabetes needs semaglutide for weight management, submitting an Ozempic PA will almost always be denied. Prescribe Wegovy and submit under the plan's weight-management criteria instead.

"A lot of plans are excluding weight loss for GLP-1s. As the indications grow for these medications, they're preferring to pay for just those specific indications." Pathik Suvarnakar, Clinical Product Ops Lead.

Common Ozempic PA Denial Reasons

74% of physicians in the AMA's survey said PA denials have increased over the past five years, according to Medical Economics. Based on the criteria above, these are the most common Ozempic-specific denial triggers.

Mistake 1: No Type 2 Diabetes Diagnosis on File

If the claim or form doesn't show a type 2 diabetes diagnosis, most plans will treat the request as weight loss and deny it. The Develop Health form's reference page flags charts coded only with obesity, BMI, prediabetes, or PCOS codes as a leading cause. 

20% had no type 2 diabetes code. Those requests were approved 13% of the time, against 79% for requests with one. They made up 52% of all Ozempic denials, and 90% of them carried an obesity, BMI, or prediabetes code instead.

How to fix it: Include the E11.x code on both the prescription and the form, and attach the note where the diagnosis was made.

Mistake 2: Missing or Stale Lab Values

A diagnosis without a supporting A1C or glucose value can trigger a denial or a request for more information. 

How to fix it: Attach a dated lab report. Some plans, such as TennCare, accept the original diagnostic A1C as long as you also document the current regimen and current A1C.

Mistake 3: Undocumented Step Therapy

"Tried metformin" without dates, dose, or outcome rarely satisfies a step-therapy requirement. 

How to fix it: Document dose, duration, adherence, and the specific reason for inadequate response, intolerance, or contraindication.

Mistake 4: Duplicate GLP-1 Therapy

A patient with an active Trulicity, Mounjaro, Wegovy, or Ozempic tablets fill will usually be denied the Ozempic pen, and vice versa. 

How to fix it: Note that the previous agent is being discontinued and give the date, so the reviewer sees a switch, not a duplication.

Mistake 5: Submitting to the Wrong Place

Sending a Medicare patient's Ozempic request to the GLP-1 Bridge, or a commercial PA to the medical plan instead of the PBM, burns days. 

How to fix it: Confirm the PBM from the BIN/PCN and match the drug to the correct pathway before submitting.

Mistake 6: Exceeding Quantity Limits During Titration

Titration can push a fill past the plan's quantity limit, especially when one prescription covers several strengths. 

How to fix it: Write a separate prescription for each strength, as the Develop Health form's reference page recommends, and check the plan's per-28-day limit before sending.

How to Appeal an Ozempic Denial

Read the denial letter first, because it names the exact criterion that wasn't met. Then address that criterion directly with new documentation, a letter of medical necessity, or a peer-to-peer review request. For Medicare Part D, a standard redetermination must be decided within 7 days and an expedited one within 72 hours, and the request can be filed on the CMS model redetermination form or in any written format.

Appeals are worth the effort, yet only 31% of physicians say they always appeal an adverse PA decision. For context, HHS Office of Inspector General data cited by Becker's found that 75% of denied prior authorization requests in Medicare Advantage were overturned on appeal, and CoverMyMeds reports that about 1 in 3 appeals submitted through its platform are approved.

How Long Does Ozempic Prior Authorization Take?

Timing depends on the channel and the plan type. Electronic submissions are consistently faster than fax or phone.

Electronic PA vs. Fax

OptumRx reports that ePA decisions can come 2-3 times faster than phone or fax, with many decisions rendered within minutes. CoverMyMeds reports that its electronic prior authorization can help patients start therapy up to 13 days sooner than manual methods.

Regulatory Deadlines

• Medicare Part D: Plans must decide within 72 hours for standard and 24 hours for expedited requests. For exception requests, the clock starts when the plan receives the prescriber's supporting statement.
  
  

• State-regulated commercial plans: Many states set their own deadlines. California, for example, deems a completed request approved if a state-regulated plan doesn't respond within 72 hours (24 hours in exigent circumstances).
  
  

• Renewals: Approvals commonly run 12 months, as in Blue Cross NC's and CVS Caremark's criteria, though some plans approve longer; Aetna approves up to 36 months. The Martin's Point TRICARE form states its Ozempic PA does not expire. Set a reminder 30 days before expiration.

Automate Ozempic Prior Authorizations with Develop Health

When your team handles dozens of GLP-1 requests a week across every major PBM, the real cost is the time spent finding the right form, pulling chart evidence, following up, and chasing denials.

This is where Develop Health comes in. Develop Health automates benefit verification and prior authorization inside your existing EHR workflow, with no app-hopping and no behavior change for your team:

• Auto-detect and auto-fill: AI finds the right payer form, pre-populates it from clinical notes, and cites the evidence for each answer.
  
  

• Submit anywhere: Requests go out via ePA, with AI fax and phone fallback for plans that don't support electronic submission.
  
  

• Chase determinations and denials: Automated follow-ups reduce "lost" PAs, and AI-generated appeal letters target the specific denial reason.
  
  

• Provider review in the EHR: Your team reviews and approves in its existing task queue.

One customer cut prescription-to-approval time from about 1.5 weeks with its previous hub vendor to roughly 20 hours, and customers report an 83% reduction in PA handling time and a 14% lift in approvals across the portfolio. Develop Health automates access for more than 400,000 patients per month and is SOC 2 Type 2 certified and HIPAA compliant.

Ready to stop filling out PA forms by hand? Book a demo with Develop Health to see Ozempic and GLP-1 prior authorizations automated end to end.

Frequently Asked Questions

Does Ozempic require prior authorization? 

Usually, yes. Most commercial, Medicare, Medicaid, and TRICARE plans require PA for Ozempic, but some pay automatically when the claim includes a type 2 diabetes diagnosis code. CVS Caremark's GLP-1 criteria use exactly this screen-out logic, and some client-specific versions, like this Caremark criteria set for Tennessee, also pass claims for patients with a recent fill of another antidiabetic drug.

Where can I find the Ozempic prior authorization form for my patient's plan? 

Start with the PBM listed on the patient's card (Express Scripts, CVS Caremark, OptumRx) or the plan's provider portal, or use the directory table above. If you can't find a plan-specific form, download our free Ozempic PA form and submit it with supporting documentation, or use an ePA portal, which works across all drugs and health plans.

Will insurance cover Ozempic for weight loss? 

Almost never. Ozempic is FDA-approved for type 2 diabetes and related cardiovascular and kidney indications, and payer policies such as Blue Cross NC's explicitly exclude use for weight loss alone. For weight management, prescribe Wegovy and follow the plan's weight-management criteria.

How long does an Ozempic prior authorization take? 

Electronic PAs can be decided within minutes to a few days, while faxed requests typically take longer. Medicare Part D plans must decide within 72 hours for standard requests and 24 hours for expedited ones.

How long is an Ozempic prior authorization good for? 

Most approvals last 12 months, though some plans approve for longer periods and at least one TRICARE plan form states the PA doesn't expire. Renewals generally require evidence that the patient is still benefiting, such as an improved A1C.

Do patients need to try metformin before Ozempic? 

It depends on the plan. Some, such as CVS Caremark's standard criteria and Aetna, require a documented metformin trial or contraindication for new starts, while others, such as Cigna's employer plans and UnitedHealthcare, don't require a metformin step.

What should I do if an Ozempic PA is denied? 

Read the denial reason, fix the specific gap with documentation or a letter of medical necessity, and resubmit or appeal. You can also request a peer-to-peer review. For Medicare Part D, the redetermination request is due within 65 days of the denial notice.

This article and form are provided for general informational purposes and are not legal, medical, or billing advice. Payer criteria change frequently. Always confirm current requirements with the patient's plan before submitting. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are registered trademarks of their respective owners.